Roche Acquires Alnylam Lab to Build RNAi Excellence Center; Buys Stake and Forges Alliance | GenomeWeb
NEW YORK (GenomeWeb News) — Roche plans to buy an Alnylam research facility in Germany, has licensed Alnylam’s RNAi IP, and will work with the RNAi company on drug-discovery projects, Roche said today.
 
Under the agreement, worth $331 million plus unknown milestones and royalties, Roche will acquire the Alnylam lab in Kulmbach, along with about 40 employees, once the deal is cleared by regulators in around 30 days, Roche said. Roche will use the site to create a Center of Excellence for RNAi therapeutics research.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.